Tango Therapeutics Inc (TNGX)
7.55
-0.24
(-3.08%)
USD |
NASDAQ |
May 17, 16:00
7.55
0.00 (0.00%)
After-Hours: 20:00
Tango Therapeutics Cash from Financing (Quarterly): 42.98M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 42.98M |
| December 31, 2023 | 1.467M |
| September 30, 2023 | 80.28M |
| June 30, 2023 | 0.586M |
| March 31, 2023 | 0.073M |
| December 31, 2022 | 0.527M |
| September 30, 2022 | 0.113M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.718M |
| March 31, 2022 | 0.257M |
| December 31, 2021 | -0.12M |
| September 30, 2021 | 327.78M |
| June 30, 2021 | -0.746M |
| March 31, 2021 | 30.41M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.746M
Minimum
Jun 2021
327.78M
Maximum
Sep 2021
37.26M
Average
0.586M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 81.74M |
| 2seventy bio Inc | 0.386M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
| iBio Inc | 4.005M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.86M |
| Cash from Investing (Quarterly) | -11.20M |
| Free Cash Flow | -122.03M |
| Free Cash Flow Per Share (Quarterly) | -0.3518 |
| Free Cash Flow to Equity (Quarterly) | -38.05M |
| Free Cash Flow to Firm (Quarterly) | -38.05M |
| Free Cash Flow Yield | -16.31% |